{"_buckets": {"deposit": "f47e4fcb-4df7-4345-ba2e-093fc696aeb0"}, "_deposit": {"id": "15484", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "15484"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00015484"}, "item_9_biblio_info_6": {"attribute_name": "\u66f8\u8a8c\u60c5\u5831", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "1988-03", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1-4", "bibliographicPageEnd": "26", "bibliographicPageStart": "17", "bibliographicVolumeNumber": "50", "bibliographic_titles": [{"bibliographic_title": "Nagoya Journal of Medical Science"}]}]}, "item_9_description_4": {"attribute_name": "\u6284\u9332", "attribute_value_mlt": [{"subitem_description": "Forty-two patients with neoplastic diseases received intravenous administration of PPD (PPD-V), and tumor markers were monitored between January, 1986 and February, 1987. Tumor markers such as CEA, AFP, SCC, CA125, IAP and polyamines decreased significantly following the PPD-V therapy. In some cases, PPD-V therapy also reduced the progression of clinical manifestation of the disease. We could not detect serum IL-2 or TNF activity. IL-2 production and sensitivity of lymphocytes were also undetectable. Intravenous administration of PPD was concluded to be effective as an adjuvant therapy against human neoplastic disease. A reduction of tumor markers was observed in 19 of the 26 assessable patients (73%). We discussed the mechanism of suppression of tumor markers by PPD-V therapy.", "subitem_description_type": "Abstract"}]}, "item_9_identifier_60": {"attribute_name": "URI", "attribute_value_mlt": [{"subitem_identifier_type": "URI", "subitem_identifier_uri": "http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/5014/5014.html"}, {"subitem_identifier_type": "HDL", "subitem_identifier_uri": "http://hdl.handle.net/2237/17502"}]}, "item_9_identifier_registration": {"attribute_name": "ID\u767b\u9332", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.18999/nagjms.50.1-4.17", "subitem_identifier_reg_type": "JaLC"}]}, "item_9_publisher_32": {"attribute_name": "\u51fa\u7248\u8005", "attribute_value_mlt": [{"subitem_publisher": "Nagoya University School of Medicine"}]}, "item_9_select_15": {"attribute_name": "\u8457\u8005\u7248\u30d5\u30e9\u30b0", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_9_source_id_61": {"attribute_name": "ISSN\uff08Online\uff09", "attribute_value_mlt": [{"subitem_source_identifier": "2186-3326", "subitem_source_identifier_type": "ISSN"}]}, "item_9_source_id_7": {"attribute_name": "ISSN\uff08print\uff09", "attribute_value_mlt": [{"subitem_source_identifier": "0027-7622", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "\u8457\u8005", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "IINUMA, MASAO"}], "nameIdentifiers": [{"nameIdentifier": "47193", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "KATO, KATSUYA"}], "nameIdentifiers": [{"nameIdentifier": "47194", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "AOKI, HIIZU"}], "nameIdentifiers": [{"nameIdentifier": "47195", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "ANDO, KOICHI"}], "nameIdentifiers": [{"nameIdentifier": "47196", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "NAKASHIMA, IZUMI"}], "nameIdentifiers": [{"nameIdentifier": "47197", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "YOSHII, SAIJI"}], "nameIdentifiers": [{"nameIdentifier": "47198", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "\u30d5\u30a1\u30a4\u30eb\u60c5\u5831", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2018-02-20"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "v50n14p17_26.pdf", "filesize": [{"value": "703.2 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 703200.0, "url": {"label": "v50n14p17_26.pdf", "url": "https://nagoya.repo.nii.ac.jp/record/15484/files/v50n14p17_26.pdf"}, "version_id": "60bc2e11-62ec-48a7-a0b5-1822af53bc13"}]}, "item_keyword": {"attribute_name": "\u30ad\u30fc\u30ef\u30fc\u30c9", "attribute_value_mlt": [{"subitem_subject": "BRM", "subitem_subject_scheme": "Other"}, {"subitem_subject": "PPD-V", "subitem_subject_scheme": "Other"}, {"subitem_subject": "suppression of tumor markers", "subitem_subject_scheme": "Other"}, {"subitem_subject": "adjuvant immunotherapy", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "\u8a00\u8a9e", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Purified Protein Derivative (PPD) Tuberculin as a Biological Response Modifier: I. Suppression of Tumor Markers by Intravenous Administration of PPD", "item_titles": {"attribute_name": "\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_title": "Purified Protein Derivative (PPD) Tuberculin as a Biological Response Modifier: I. Suppression of Tumor Markers by Intravenous Administration of PPD"}]}, "item_type_id": "9", "owner": "1", "path": ["499/508/509/1461"], "permalink_uri": "https://doi.org/10.18999/nagjms.50.1-4.17", "pubdate": {"attribute_name": "\u516c\u958b\u65e5", "attribute_value": "2013-02-13"}, "publish_date": "2013-02-13", "publish_status": "0", "recid": "15484", "relation": {}, "relation_version_is_last": true, "title": ["Purified Protein Derivative (PPD) Tuberculin as a Biological Response Modifier: I. Suppression of Tumor Markers by Intravenous Administration of PPD"], "weko_shared_id": 3}